Balyasny Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Balyasny Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	+14,915	New	+$200K	﹤0.01%	2801
2023 Q4	–	Sell	-42,064	Closed	-$470K	–	2590
2023 Q3	$470K	Buy	+42,064	New	+$677K	﹤0.01%	1776
2019 Q3	–	Sell	-11,013	Closed	-$929K	–	1282
2019 Q2	$929K	Buy	11,013 +1,210	+12%	+$109K	0.01%	1097
2019 Q1	$936K	Buy	+9,803	New	+$879K	0.01%	1043
2015 Q2	–	Sell	-148,610	Closed	-$4.55M	–	1194
2015 Q1	$4.55M	Buy	+148,610	New	+$5.78M	0.04%	488

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Balyasny Asset Management's ENTA Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2026: 14,915 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #2801 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ENTA as recently as Q3 2023.

Balyasny Asset Management first reported a position in ENTA in Q1 2015 and has held it in 5 quarters since. The position peaked at $4.55M in Q1 2015. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Balyasny Asset Management held 14,915 shares of Enanta Pharmaceuticals worth $217K as of Q2 2026.
Enanta Pharmaceuticals was a new Balyasny Asset Management position in Q2 2026.
Enanta Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2801 holding.
Balyasny Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and has held it in 5 quarters since.
Balyasny Asset Management's Enanta Pharmaceuticals position peaked at $4.55M in Q1 2015.
123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.